Phase II single centre study assessing the efficacy and safety of I-131 rituximab radioimmunotherapy of relapsed or refractory, CD 20 positive, diffuse large B cell lymphoma, with the primary objective tumour response.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Rituximab (Primary) ; Anti-CD20 monoclonal antibody C2B8-I-131
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms RITRAL
- Sponsors Roche
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 30 Aug 2011 New trial record